Efficacy and safety of stem cell transplantation for multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials

• Published in: Scientific reports Vol. 14; no. 1; pp. 12545 - 14
• Main Authors: Nawar, Asmaa Ahmed, Farid, Aml Mostafa, Wally, Rim, Tharwat, Engy K., Sameh, Ahmed, Elkaramany, Yomna, Asla, Moamen Mostafa, Kamel, Walaa A.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 31.05.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 692/308/2171; 692/617; 692/617/375/1411/1666; Autoimmune diseases; Clinical trials; Hematological diseases; Hematology; Humanities and Social Sciences; Humans; Immune system; Immunomodulation; Immunosuppression; Lesions; Meta-analysis; Motor task performance; multidisciplinary; Multiple sclerosis; Multiple Sclerosis - therapy; Neurological diseases; Patients; Randomized Controlled Trials as Topic; Risk assessment; Science; Science (multidisciplinary); Sensitivity analysis; Sensorimotor integration; Stem cell transplantation; Stem Cell Transplantation - adverse effects; Stem Cell Transplantation - methods; Stem cells; Systematic review; Transplantation; Treatment Outcome
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-62726-4

Multiple sclerosis (MS) is a common autoimmune neurological disease affecting patients’ motor, sensory, and visual performance. Stem Cell Transplantation (SCT) is a medical intervention where a patient is infused with healthy stem cells with the purpose of resetting their immune system. SCT shows remyelinating and immunomodulatory functions in MS patients, representing a potential therapeutic option. We conducted this systematic review and meta-analysis that included randomized control trials (RCTs) of SCT in MS patients to investigate its clinical efficacy and safety, excluding observational and non-English studies. After systematically searching PubMed, Web of Science, Scopus, and Cochrane Library until January 7, 2024, nine RCTs, including 422 patients, were eligible. We assessed the risk of bias (ROB) in these RCTs using Cochrane ROB Tool 1. Data were synthesized using Review Manager version 5.4 and OpenMeta Analyst software. We also conducted subgroup and sensitivity analyses. SCT significantly improved patients expanded disability status scale after 2 months (N = 39, MD =  − 0.57, 95% CI [− 1.08, − 0.06], p  = 0.03). SCT also reduced brain lesion volume (N = 136, MD = − 7.05, 95% CI [− 10.69, − 3.4], p  = 0.0002). The effect on EDSS at 6 and 12 months, timed 25-foot walk (T25-FW), and brain lesions number was nonsignificant. Significant adverse events (AEs) included local reactions at MSCs infusion site (N = 25, RR = 2.55, 95% CI [1.08, 6.03], p  = 0.034) and hematological disorders in patients received immunosuppression and autologous hematopoietic SCT (AHSCT) (N = 16, RR = 2.33, 95% CI [1.23, 4.39], p  = 0.009). SCT can improve the disability of MS patients and reduce their brain lesion volume. The transplantation was generally safe and tolerated, with no mortality or significant serious AEs, except for infusion site reactions after mesenchymal SCT and hematological AEs after AHSCT. However, generalizing our results is limited by the sparse number of RCTs conducted on AHSCT. Our protocol was registered on PROSPERO with a registration number: CRD42022324141.